专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040116347A1 Methods of assaying for modulators of the inflammatory process using components of the ubiquitin ligation cascade 有权
标题翻译：使用泛素连接级联的组分测定炎症过程的调节剂的方法
公开(公告)号：US20040116347A1
公开(公告)日：2004-06-17
申请号：US10652961
申请日：2003-08-28
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Esteban Masuda , Brian Wong
IPC分类号： C12Q001/68 , G01N033/53 , G01N033/567
CPC分类号： G01N33/5011 , C12Q1/6883 , C12Q2600/158 , G01N33/5008 , G01N33/502 , G01N33/5047 , G01N33/5091 , G01N33/6893 , G01N2333/9015 , G01N2510/00
摘要： The present invention relates to regulation of inflammation. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of the inflammatory process. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate the inflammatory process via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to regulation of inflammation and modulation of cytokine signaling involved in inflammation, e.g., for treatment of infection, autoimmune disease and other diseases related to the inflammatory process.
摘要翻译：本发明涉及炎症的调节。更具体地，本发明涉及编码泛素连接途径的组分的核酸，例如涉及炎症过程调节的泛素和泛素样分子，E1，E2和E3蛋白及其底物。本发明还涉及用于鉴别和使用通过调节泛素连接途径调节炎症过程的试剂，包括小分子化学组合物，抗体，肽，环肽，核酸，RNAi，反义核酸和核酶的方法; 以及在与炎症调节相关的诊断和治疗相关的诊断和治疗中使用表达谱和组合物，例如用于治疗感染，自身免疫性疾病和与炎症过程相关的其它疾病。

2. 发明申请

US20030109440A1 GRB7: novel regulator of lymphocyte signaling 审中-公开
标题翻译： GRB7：淋巴细胞信号传导的新型调节因子
公开(公告)号：US20030109440A1
公开(公告)日：2003-06-12
申请号：US10233098
申请日：2002-08-30
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Peter Chu , Congfen Li , X. Charlene Liao , Esteban Masuda , Jorge Pardo , Haoran Zhao
IPC分类号： A61K038/17 , G01N033/53 , C12Q001/68 , G01N033/567
CPC分类号： C07K14/4713 , G01N33/505 , G01N2333/4706 , G01N2500/10
摘要： The present invention relates to regulation of T lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding GRB7, which is involved in modulation of T lymphocyte activation and TCR signaling. The invention further relates to methods for identifying and using agents, including small organic molecules, peptides, circular peptides, antibodies, lipids, antisense nucleic acids, RNAi, and ribozymes, that modulate lymphocyte activation and TCR signaling via modulation of GRB7; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression.
摘要翻译：本发明涉及T淋巴细胞活化的调控。更具体地，本发明涉及编码GRB7的核酸，其参与T淋巴细胞活化和TCR信号传导的调节。本发明还涉及用于鉴定和使用通过调节GRB7来调节淋巴细胞活化和TCR信号的试剂，包括小有机分子，肽，环状肽，抗体，脂质，反义核酸，RNAi和核酶的方法; 以及在与淋巴细胞活化和抑制相关的诊断和治疗中使用表达谱和组合物。

3. 发明申请

US20020156003A1 Modulators of angiogenesis 有权
标题翻译：血管生成调节剂
公开(公告)号：US20020156003A1
公开(公告)日：2002-10-24
申请号：US09935124
申请日：2001-08-21
申请人： Rigel Pharmaceuticals, Incorporated
发明人： James B. Lorens , Weiduan Xu , Robert E. Atchison , Jakob Bogenberger
IPC分类号： C12Q001/68 , G01N033/53 , A61K039/395 , G01N033/567 , A61K038/17
CPC分类号： C12Q1/42 , A61K38/00 , G01N2500/02 , G01N2500/10 , G01N2500/20
摘要： The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (nullILKAPnull) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.
摘要翻译：本发明涉及血管发生的调节。更具体地，本发明涉及编码C1-血管发生蛋白的核酸，也称为整合素连接的激酶相关蛋白（“ILKAP”）和ILKAP蛋白，其涉及血管发生的调节。本发明进一步涉及用于鉴定和使用通过调节ILKAP和ILKAP相关级联来调节血管生成的试剂，包括小有机分子，抗体，肽，环肽，核酸，反义核酸和核酶的方法; 以及在血管生成诊断和治疗中使用表达谱和组合物。

4. 发明申请

US20040126850A1 Directed evolution of protein in Mammalian cells 有权
标题翻译：哺乳动物细胞中蛋白质的定向进化
公开(公告)号：US20040126850A1
公开(公告)日：2004-07-01
申请号：US10739656
申请日：2003-12-17
申请人： Rigel Pharmaceuticals, Incorporated , Becton, Dickinson and Company
发明人： Beau Peelle
IPC分类号： C07H021/04 , C07K014/47 , C12N005/06
CPC分类号： C12N15/1096
摘要： The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
摘要翻译：本发明涉及哺乳动物细胞中的定向蛋白进化和改良的Discosoma sp。红色荧光蛋白。

5. 发明申请

US20040053233A1 Modulators of angiogenesis 有权
标题翻译：血管生成调节剂
公开(公告)号：US20040053233A1
公开(公告)日：2004-03-18
申请号：US10231956
申请日：2002-08-30
申请人： Rigel Pharmaceuticals, Incorporated
发明人： James B. Lorens , Weiduan Xu , Jakob Bogenberger , Sacha Holland
IPC分类号： C12Q001/68
CPC分类号： C12Q1/6883 , C07K14/4702 , C12Q2600/158
摘要： The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding nullangiogenesis regulatory proteins and nucleic acidsnull which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
摘要翻译：本发明涉及血管发生的调节。更具体地，本发明涉及编码血管发生调节的“血管发生调节蛋白和核酸”的核酸。本发明还涉及用于鉴定和使用通过调节血管发生调节蛋白和核酸来调节血管生成的试剂，包括小有机分子，抗体，肽，环肽，核酸，反义核酸，RNAi和核酶的方法; 以及在血管生成相关疾病的诊断和治疗中使用表达谱和组合物。

6. 发明申请

US20030077730A1 Directed evolution of protein in mammalian cells 失效
标题翻译：蛋白质在哺乳动物细胞中的定向进化
公开(公告)号：US20030077730A1
公开(公告)日：2003-04-24
申请号：US10152296
申请日：2002-05-20
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Beau Peelle
IPC分类号： C12Q001/68 , C07H021/04 , C12P021/02 , C12N005/06 , C07K014/435
CPC分类号： C12N15/1096
摘要： The present invention relates to directed protein evolution in mammalian cells and improved mutants of Discosoma sp. red fluorescent proteins.
摘要翻译：本发明涉及哺乳动物细胞中的定向蛋白进化和改良的Discosoma sp。红色荧光蛋白。

7. 发明申请

US20030013107A1 Alpha 2 integrin: modulators of lymphocyte activation 审中-公开
标题翻译： α2整合素：淋巴细胞活化的调节剂
公开(公告)号：US20030013107A1
公开(公告)日：2003-01-16
申请号：US10160354
申请日：2002-05-30
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Peter Chu , Congfen Li , X. Charlene Liao , Jorge Pardo
IPC分类号： C12Q001/68 , G01N033/567 , C12N005/08
CPC分类号： G01N33/505 , G01N33/68 , G01N2333/70546 , G01N2333/7055
摘要： The present invention relates to regulation of T cell activation. More particularly, the present invention is directed to nucleic acids encoding alpha 2 integrin. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate T cell activation via modulation of alpha 2 integrin and alpha 2 integrin-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to autoimmune disease and tissue and organ transplant.
摘要翻译：本发明涉及T细胞活化的调控。更具体地，本发明涉及编码α2整联蛋白的核酸。本发明还涉及用于鉴定和使用包括小分子化学组成，抗体，siRNA，反义核酸和核酶的试剂的方法，其通过调节α2整联蛋白和α2整联蛋白相关信号转导来调节T细胞活化; 以及在与自身免疫疾病和组织和器官移植相关的诊断和治疗中使用表达谱和组合物。

8. 发明申请

US20040126784A1 Modulators of cellular proliferation 审中-公开
公开(公告)号：US20040126784A1
公开(公告)日：2004-07-01
申请号：US10620052
申请日：2003-07-14
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Yasumichi Hitoshi , Yonchu Jenkins , Vadim Markovtsov
IPC分类号： C12Q001/68 , G01N033/53 , G01N033/567
CPC分类号： G01N33/5011
摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding protein kinase C null (PKC-null), phospholipase C-null1 (PLC-null1), protein tyrosine kinase 2 (FAK), protein tyrosine kinase 2b (FAK2), casein kinase 2 (CK2), cMET tyrosine kinase (cMET), flap structure specific endonuclease 1 (FEN1), REV1 dCMP transferase (REV1), apurinic/apyrimidinic nuclease 1 (APE1), cyclin dependent kinase 3 (CDK3), PIM1 kinase (PIM1), cell division cycle 7 kinase (CDC7L1), cyclin dependent kinase 7 (CDK7), cytokine inducible kinase (CNK), potentially prenylated protein tyrosine phosphatase (PRL-3), serine threonine kinase 2 (STK2) or (NEK4), cyclin dependent serine threonine kinase (NKIAMRE), or histone acetylase (HBO1), which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of protein kinase C null (PKC-null), phospholipase C-null1 (PLC-null1), protein tyrosine kinase 2 (FAK), protein tyrosine kinase 2b (FAK2), casein kinase 2 (CK2), cMET tyrosine kinase (cMET), flap structure specific endonuclease 1 (FEN1), REV1 dCMP transferase (REV1), apurinic/apyrimidinic nuclease 1 (APE1), cyclin dependent kinase 3 (CDK3), PIM1 kinase (PIM1), cell division cycle 7 kinase (CDC7L1), cyclin dependent kinase 7 (CDK7), cytokine inducible kinase (CNK), potentially prenylated protein tyrosine phosphatase (PRL-3), serine threonine kinase 2 (STK2) or (NEK4), cyclin dependent serine threonine kinase (NKIAMRE), or histone acetylase (HBO1), as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

9. 发明申请

US20030176333A1 CASPR3: modulators of angiogenesis 审中-公开
标题翻译： CASPR3：血管生成调节剂
公开(公告)号：US20030176333A1
公开(公告)日：2003-09-18
申请号：US10100818
申请日：2002-03-18
申请人： Rigel Pharmaceuticals, Incorporated
发明人： James B. Lorens , Weiduan Xu , Jakob Bogenberger
IPC分类号： A61K038/16 , C12Q001/68 , G01N033/53 , G01N033/567
CPC分类号： G01N33/566 , A61K38/1787 , G01N2500/04 , G01N2800/7014
摘要： The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding contactin associated protein 3 (CASPR3), which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of CASPR3; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
摘要翻译：本发明涉及血管发生的调节。更具体地，本发明涉及编码与血管生成调节有关的接触蛋白相关蛋白3（CASPR3）的核酸。本发明还涉及用于鉴定和使用通过调节CASPR3调节血管生成的试剂，包括小有机分子，抗体，肽，环肽，核酸，反义核酸，RNAi和核酶的方法; 以及在血管生成相关疾病的诊断和治疗中使用表达谱和组合物。

10. 发明申请

US20030027763A1 CD43: modulators of mast cell degranulation 审中-公开
标题翻译： CD43：肥大细胞脱粒的调节剂
公开(公告)号：US20030027763A1
公开(公告)日：2003-02-06
申请号：US10161165
申请日：2002-05-31
申请人： Rigel Pharmaceuticals, Incorporated
发明人： Mark Bennett , Sacha Holland , Alex Rossi
IPC分类号： G01N033/567 , A61K038/17
CPC分类号： C07K14/70596 , A61K38/00
摘要： The present invention relates to regulation of IgE-receptor-mediated mast cell degranulation. More particularly, the present invention is directed to nucleic acids encoding CD43 (also called leukosialin or leukocyte large sialoglycoprotein), which is involved in modulation of IgE-receptor-mediated mast cell degranulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate IgE-receptor-mediated mast cell degranulation via modulation of CD43 and CD43-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to diseases such as allergies and asthma.
摘要翻译：本发明涉及IgE受体介导的肥大细胞脱粒的调节。更具体地，本发明涉及编码CD43（也称为白血球蛋白或白细胞大唾液酸糖蛋白）的核酸，其涉及调节IgE受体介导的肥大细胞脱粒。本发明还涉及用于鉴定和使用通过调节CD43和CD43相关信号转导调节IgE受体介导的肥大细胞脱粒的试剂，包括小分子化学组合物，抗体，siRNA，反义核酸和核酶的方法; 以及在与诸如过敏和哮喘等疾病相关的诊断和治疗中使用表达谱和组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式